1-20 of 181
N Shah
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

How I treat refractory CRS and ICANS after CAR T-cell therapy

Clinical Trials & Observations
Michael D. Jain, Melody Smith, Nirali N. Shah
Journal: Blood
Blood (2023) 141 (20): 2430–2442.
DOI: https://doi.org/10.1182/blood.2022017414
Published: 2023
Journal Articles

How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL

Regina M. Myers, Nirali N. Shah, Michael A. Pulsipher
Journal: Blood
Blood (2023) 141 (11): 1251–1264.
DOI: https://doi.org/10.1182/blood.2022016937
Published: 2023
Journal Articles

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Anthony R. Mato, Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Krish Patel, Toby A. Eyre, Talha Munir, Ewa Lech-Marańda, Nicole Lamanna, Constantine S. Tam, John F. Seymour, Nirav N. Shah, Catherine C. Coombs, Chaitra S. Ujjani, Manish R. Patel, Bita Fakhri, Chan Y. Cheah, Alvaro J. Alencar, Jonathon B. Cohen, James N. Gerson, Ian W. Flinn, Shuo Ma, Deepa Jagadeesh, Joanna M. Rhodes, Francisco Hernandez-Ilizaliturri, Pier Luigi Zinzani, Minna Balbas, Binoj Nair, Paolo B. Abada, Chunxiao Wang, Denise Wang, Donald E. Tsai, William G. Wierda, Wojciech Jurczak
Journal: Blood
Blood (2022) 140 (Supplement 1): 2316–2320.
DOI: https://doi.org/10.1182/blood-2022-159497
Published: 2022
Journal Articles

Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India

Atharva Karulkar, Hasmukh Jain, Shreshtha Shah, Aalia Khan, Ankesh Jaiswal, Afrin Firfiray, Prashant Suvasia, Priyanshi Suvasia, Juber Pendhari, Sweety Asija, Ambalika Chowdury, Ankit Banik, Smrithi Ravikumar, Neha Sharma, Minal Poojary, Sumathi Hiregoudar, Preeti Desai, Anisha Navkudkar, Sunil Rajadhyaksha, Jayashree Thorat, Prashant R. Tembhare, Albeena Nisar, Manju Sengar, David F. Stroncek, Steven Highfill, Nirali N. Shah, Gaurav Narula, Rahul Purwar
Journal: Blood
Blood (2022) 140 (Supplement 1): 4610–4611.
DOI: https://doi.org/10.1182/blood-2022-168928
Published: 2022
Journal Articles

MRD Status By Clonoseq ® Is a Poor Predictor of Long-Term Outcomes after Bispecific LV20.19 CAR T-Cell Therapy for Relapsed, Refractory B-Cell NHL

Fateeha Furqan, Timothy S. Fenske, Walter L. Longo, Bryon Johnson, Mehdi Hamadani, Nirav N. Shah
Journal: Blood
Blood (2022) 140 (Supplement 1): 6407–6408.
DOI: https://doi.org/10.1182/blood-2022-170047
Published: 2022
Journal Articles

Results from a Phase 1/2 Study of Tandem, Bispecific Anti-CD20/Anti-CD19 (LV20.19) CAR T-Cells for Mantle Cell Lymphoma

Nirav N. Shah, Fateeha Furqan, Aniko Szabo, Jessica Neumann, Parameswaran Hari, Dina Schneider, Bryon Johnson, Mehdi Hamadani, Timothy S. Fenske
Journal: Blood
Blood (2022) 140 (Supplement 1): 9318–9319.
DOI: https://doi.org/10.1182/blood-2022-158695
Published: 2022
Journal Articles

Single Cell Cytokine Analyses of Bispecific, Tandem, Anti-CD20, Anti-CD19 CAR T-Cells from Patients with Relapsed, Refractory B-Cell Malignancies

Fateeha Furqan, Huiqing Xu, Joanna Zurko, Timothy S. Fenske, Bryon Johnson, Mehdi Hamadani, Nirav N. Shah
Journal: Blood
Blood (2022) 140 (Supplement 1): 12690–12691.
DOI: https://doi.org/10.1182/blood-2022-169198
Published: 2022
Journal Articles

Phase I Trial of Humanized CD19 CART-Cell Therapy Developed in India: Safe, Active and Feasible for Outpatient Therapy

Hasmukh Jain, Atharva Karulkar, Neha Sharma, Manju Sengar, Ankesh Jaiswal, Shreshtha Shah, Aalia Khan, Afrin Firfiray, Sweety Asija, Prashant Suvasia, Priyanshi Suvasia, Juber Pendhari, Devanshi Kalra, Smrithi Ravikumar, Gaurav Narula, Shripad Banavali, Minal Poojary, Sumathi Hiregoudar, Lingaraj Nayak, Bhausaheb Bagal, Prashant R. Tembhare, Sridhar Epari, Navin Khattry, Nikhil Patkar, Sumeet Gujral, Tanuja Shet, Papagudi Ganesan Subramanian, Jayashree Thorat, Sachin Punatar, Anant Gokarn, Kinjalka Ghosh, Archi Agarwal, Preeti Desai, Shashank Ojha, Subhash Yadav, Shil Pushp Bhosale, Sunil Rajadhyaksha, Anisha Navkudkar, Siddharth Laskar, Sumeet Prakash Mirgh, Albeena Nisar, Deepali Pandit, Ruchira Patil, Rahul Purwar, Sattva S. Neelapu, Nirali N. Shah
Journal: Blood
Blood (2022) 140 (Supplement 1): 10332–10334.
DOI: https://doi.org/10.1182/blood-2022-166082
Published: 2022
Journal Articles

Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy

Ishan Roy, Narendranath Epperla, Geoffrey Shouse, Jason T. Romancik, Tamara K. Moyo, Vaishalee P. Kenkre, Thomas A. Ollila, Lindsey A. Fitzgerald, Brian T. Hess, Andrew M. Evens, Joanna Zurko, Sayan Mullick Chowdhury, Kaitlin Annunzio, Robert Ferdman, Rahul S. Bhansali, Elyse I. Harris, McKenzie Sorrell, Jieqi Liu, Imran A. Nizamuddin, Jonathan Moreira, Shuo Ma, Jane N. Winter, Barbara Pro, Deborah M. Stephens, Alexey V Danilov, Nirav N. Shah, Jonathon B. Cohen, Stefan K. Barta, Pallawi Torka, Leo I. Gordon, Reem Karmali
Journal: Blood
Blood (2022) 140 (Supplement 1): 2416–2418.
DOI: https://doi.org/10.1182/blood-2022-163822
Published: 2022
Journal Articles

Phase I Study of Tagraxofusp with or without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123-Expressing Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial

Adam J. Lamble, Yueh-Yun Chi, Bill H. Chang, Anupam Verma, Kelly E Faulk, Alexandra McLean Stevens, Lauren Pommert, Sarah Tucker, Benjamin Brookhart, Nirali N. Shah, Christopher L. Brooks, Tariq I. Mughal, Alan S. Wayne, Soheil Meshinchi, Todd M. Cooper
Journal: Blood
Blood (2022) 140 (Supplement 1): 6102–6103.
DOI: https://doi.org/10.1182/blood-2022-163503
Published: 2022
Journal Articles

Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis Is an Effective Surveillance Tool in Patients with Mantle Cell Lymphoma

Alexandra Rezazadeh, Mehdi Hamadani, Nirav N. Shah, Timothy S. Fenske
Journal: Blood
Blood (2022) 140 (Supplement 1): 10710–10711.
DOI: https://doi.org/10.1182/blood-2022-162903
Published: 2022
Journal Articles

Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition

Sarah Aminov, Orsi Giricz, R. Alejandro Sica, Veronika Polishchuk, Bonnie Yates, Hao-Wei Wang, Yanhua Wang, Srabani Sahu, Shanisha Gordon, Carolina Schinke, Kith Pradhan, Srinivas Aluri, Murali Janakiram, Stefan K. Barta, Beamon Agarwal, Mendel Goldfinger, Aditi Shastri, William Matsui, Ulrich Steidl, Joshua Brody, Nirali N. Shah, Samir Parekh, Amit Verma
Journal: Blood
Blood (2022) 140 (Supplement 1): 3480–3482.
DOI: https://doi.org/10.1182/blood-2022-169102
Published: 2022
Journal Articles

Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy

Joanna Zurko, Geoffrey Shouse, Pallawi Torka, Tamara K. Moyo, Jason T. Romancik, Imran A. Nizamuddin, Kaitlin Annunzio, Jieqi Liu, Stefan K. Barta, Robert Ferdman, Rahul Bhansali, Jonathon B. Cohen, Sayan Mullick Chowdhury, Nirav N. Shah, Elyse I. Harris, Vaishalee P. Kenkre, McKenzie Sorrell, Brian T. Hess, Deborah M. Stephens, Lindsey A. Fitzgerald, Thomas A. Ollila, Ishan Roy, Shuo Ma, Jane N. Winter, Barbara Pro, Jonathan Moreira, Leo I. Gordon, Alexey V Danilov, Andrew M. Evens, Narendranath Epperla, Reem Karmali
Journal: Blood
Blood (2022) 140 (Supplement 1): 375–377.
DOI: https://doi.org/10.1182/blood-2022-163438
Published: 2022
Journal Articles

Challenges in Treatment Decisions and Patient-Provider Communication in Relapsed/Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Nirav N. Shah, Sophie Peloquin, Florence Cymbalista, Martin Dreyling, Suzanne Murray, Romano Del Fiacco, Patrice Lazure
Journal: Blood
Blood (2022) 140 (Supplement 1): 13106–13108.
DOI: https://doi.org/10.1182/blood-2022-166804
Published: 2022
Journal Articles

Trial in Progress: A First-in-Human Phase 1/2 Study of Hematopoietic Stem Cell Transplantation (HCT) with VOR33 (CD33-Deleted Allograft) Followed By Treatment with Gemtuzumab Ozogamicin (GO) in Patients with CD33+ Acute Myeloid Leukemia (AML) Who Are at High-Risk of Post-HCT Relapse

Brenda W. Cooper, Hyung C. Suh, Divya Koura, Guenther Koehne, Christina Cho, Nadia M. Bambace, Léa Bernard, Nirali N. Shah, Roland B. Walter, John F. DiPersio, Sritama Nath, Melissa M. Lee-Sundlov, Ali Lacy, Darren Stanizzi, Karen Kuhn, Jennifer S. Whangbo, Christopher Slapak, Glen D. Raffel
Journal: Blood
Blood (2022) 140 (Supplement 1): 12973–12975.
DOI: https://doi.org/10.1182/blood-2022-165289
Published: 2022
Journal Articles

8-Day Versus 12-Day Manufactured LV20.19 CAR T-Cells for B-Cell Non-Hodgkin Lymphoma

Nirav N. Shah, Fateeha Furqan, Aniko Szabo, Jessica Neumann, Walter L. Longo, Parameswaran Hari, Dina Schneider, Bryon Johnson, Timothy S. Fenske, Mehdi Hamadani
Journal: Blood
Blood (2022) 140 (Supplement 1): 7480–7481.
DOI: https://doi.org/10.1182/blood-2022-169119
Published: 2022
Journal Articles

Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study

Nirav N. Shah, Michael L. Wang, Jennifer R. Brown, Krish Patel, Jennifer A. Woyach, William G. Wierda, Chaitra S. Ujjani, Toby A. Eyre, Pier Luigi Zinzani, Alvaro J. Alencar, Thomas Gastinne, Paolo Ghia, Nicole Lamanna, Marc Hoffmann, Manish R. Patel, Ian W. Flinn, James N. Gerson, Shuo Ma, Catherine C. Coombs, Chan Y. Cheah, Ewa Lech-Marańda, Bita Fakhri, Won-Seog Kim, Minal A. Barve, Jonathon B. Cohen, Wojciech Jurczak, Talha Munir, Meghan C. Thompson, Lindsey E. Roeker, Katherine Bao, Nicholas A. Cangemi, Jennifer F. Kherani, Richard A. Walgren, Hongmei Han, Amy S. Ruppert, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 4127–4132.
DOI: https://doi.org/10.1182/blood-2022-159035
Published: 2022
Journal Articles

Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309

Annie Im, Daniel Wolff, Corey Cutler, Robert Zeiser, Nirav N. Shah, Ming Tony Tan, Jaime Sanz, Haris Ali, Giuseppe Milone, Arjun D. Law, Domenico Russo, Eva-Maria Wagner, Olga Ivanova, Kevin Hou, Maureen Bleam, Rodica Morariu-Zamfir, Steven Z Pavletic
Journal: Blood
Blood (2022) 140 (Supplement 1): 1870–1871.
DOI: https://doi.org/10.1182/blood-2022-169605
Published: 2022
Journal Articles

Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy

Reem Karmali, Narendranath Epperla, Geoffrey Shouse, Jason T. Romancik, Tamara K. Moyo, Vaishalee P. Kenkre, Thomas A. Ollila, Lindsey A. Fitzgerald, Brian T. Hess, Andrew M. Evens, Ishan Roy, Joanna Zurko, Sayan Mullick Chowdhury, Kaitlin Annunzio, Robert Ferdman, Rahul Bhansali, Elyse I. Harris, McKenzie Sorrell, Jieqi Liu, Imran A. Nizamuddin, Shuo Ma, Jonathan Moreira, Jane N. Winter, Barbara Pro, Deborah M. Stephens, Alexey V Danilov, Nirav N. Shah, Jonathon B. Cohen, Stefan K. Barta, Pallawi Torka, Leo I. Gordon
Journal: Blood
Blood (2022) 140 (Supplement 1): 10955–10957.
DOI: https://doi.org/10.1182/blood-2022-160431
Published: 2022
Journal Articles

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study

William G. Wierda, David John Lewis, Paolo Ghia, Nirav N. Shah, Catherine C. Coombs, Chan Y. Cheah, Nicole Lamanna, Joanna M. Rhodes, Marc Hoffmann, Shuo Ma, Toby A. Eyre, Talha Munir, Manish R. Patel, Alvaro J. Alencar, Constantine S. Tam, John F. Seymour, Wojciech Jurczak, Ewa Lech-Marańda, Lindsey E. Roeker, Philip A. Thompson, Paolo B. Abada, Chunxiao Wang, Binoj Nair, Hui Liu, Donald E. Tsai, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 846–849.
DOI: https://doi.org/10.1182/blood-2022-157058
Published: 2022